Aminoglycoside therapy in infectious diseases

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 12, 2013, Pages 1585-1597

  Poulikakos, Panagiotis ^a   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b MITERA HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACHN 490; Aminoglycoside; Antibiotics; Gram negative; Infection; Multidrug resistant; Plazomicin; Synergy

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; HABEKACIN; IMIPENEM; ISEPAMICIN; KANAMYCIN; MEROPENEM; METALLO BETA LACTAMASE; METRONIDAZOLE; NEOMYCIN; NETILMICIN; PAROMOMYCIN; PLAZOMICIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RNA 16S; STREPTOMYCIN; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL INFECTION; ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; AUDIOMETRY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BARTONELLOSIS; BOTULISM; BRUCELLOSIS; BURKHOLDERIA CEPACIA; CARRION DISEASE; CLINICAL PRACTICE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; EAR INFECTION; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI; EYE INFECTION; GENETIC SCREENING; GRAM NEGATIVE BACTERIUM; HEARING IMPAIRMENT; HUMAN; HYPEROSMOLARITY; HYPOCALCEMIA; INFECTION; KIDNEY BLOOD FLOW; KLEBSIELLA; MENINGITIS; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEISSERIA GONORRHOEAE; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NYSTAGMUS; OSTEOMYELITIS; OTOTOXICITY; PELVIC INFLAMMATORY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PLAGUE; POSTANTIBIOTIC EFFECT; PROTEUS MIRABILIS; PROTOZOAL INFECTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SEPTIC SHOCK; SKIN LEISHMANIASIS; STENOTROPHOMONAS MALTOPHILIA; SURGICAL INFECTION; TINNITUS; TUBERCULOSIS; TULAREMIA; URINARY TRACT INFECTION; VERTIGO;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COMMUNICABLE DISEASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84880261782     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.806486     Document Type: Review

References (100)

1. Davies J, Wright GD. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 1997;5(6):234-40
2. Hamilton-Miller JM, Shah S. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1995;35(6):865-8
3. Cohen-Kerem R, Kisilevsky V, Einarson TR, et al Intratympanic gentamicin for Meniere's disease: a meta-analysis. Laryngoscope 2004;114(12):2085
4. Wilschanski M, Yahav Y, Yaacov Y, et al Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349(15):1433-41
5. Malik V, Rodino-Klapac L, Viollet L, Mendell J. Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther Adv Neurol Disord 2010;3(6):379-89
6. Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME. Do we still need the aminoglycosides? Int J Antimicrob Agents 2009;33(3):201-5
7. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999;43(4):727-37
8. Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 2007;64(14):1841-52
9. Oliveira JF, Cipullo JP, Burdmann EA. Aminoglycoside nephrotoxicity. Braz J Cardiovasc Surg 2006;21(4):444-52
10. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27(1):23-7
11. Karlowsky JA, Zelenitsky SA, Zhanel GG. Aminoglycoside adaptive resistance. Pharmacotherapy 1997;17(3):549-55
12. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988;33(4):900-11
13. Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011;79(1):33-45
14. Levin ML. Aminoglycoside nephrotoxicity: keys to prevention. J Crit Illn 1994;9(10):911-2, 915
15. Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res 2011;281(1-2):28-37
16. Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007;72(8):931-5
17. Usami S, Abe S, Akita J, et al. Prevalence of mitochondrial gene mutations among hearing impaired patients. J Med Genet 2000;37(1):38-40
18. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002;6(7):622-7
19. Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. J Kidney Int 2007;72(3):359
20. Chen Y, Huang WG, Zha DJ, et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res 2007;226(1-2):178-82
21. Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A->G mutation in European children. N Engl J Med 2009;360(6):640-2
22. Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005;40(1):127-35
23. The Medical Letter. Antimicrobial prophylaxis for surgery. Treat Guide Med Lett 2012;10(122):73-8
24. Hobbie S N, Kaiser M, Schmidt S, et al. Genetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against leishmania and trypanosoma. PLoS Negl Trop Dis 2011;5(5):e1161
25. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical Paromomycin with or without Gentamicin for Cutaneous Leishmaniasis. N Engl J Med 2013;368:524-32
26. Falagas ME, Siempos II, Bliziotis IA, Michalopoulos A. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit Care 2006;10(4):R123
27. Falagas ME, Agrafiotis M, Athanassa Z, Siempos II. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev Anti Infect Ther 2008;6(4):447-52
28. Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007;60(6):1216-26
29. Michalopoulos A, Metaxas EI, Falagas ME. Aerosol delivery of antimicrobial agents during mechanical ventilation: current practice and perspectives. Curr Drug Deliv 2011;8(2):208-12
30. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416
31. Conway SP. Nebulized antibiotic therapy: the evidence. Chron Respir Dis 2005;2(1):35-41
32. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312(7027):338-45
33. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996;124(8):717-25
34. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39(6):677-86
35. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2012;2:CD002009-doi: 10.1002/14651858
36. Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2011;11):CD005091
37. Perez V, Saenz D, Madriz J, et al. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica. Int J Infect Dis 2011;15(8):e569-75
38. Best EJ, Gazarian M, Cohn R, et al. Once-daily gentamicin in infants and children: a prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity. Pediatr Infect Dis J 2011;30(10):827-32
39. Banerjee S, Narayanan M, Gould K. Monitoring aminoglycoside level. BMJ 2012;345:e6354
40. Begg EJ, Barclay ML. Aminoglycosides-50 years on. Br J Clin Pharmacol 1995;39(6):597-603
41. Baddour LM, Wilson WR, Bayer AS, et al. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111(23):e394-434
42. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995;39(3):650-5
43. McCormack JP. An emotional-based medicine approach to monitoring once-daily aminoglycosides. Pharmacotherapy 2000;20(12):1524-7
44. Georghiou SB, Magana M, Garfein RS, et al. Evaluation of genetic mutations associated with mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012;7(3):e33275
45. Wachino J, Arakawa Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. Drug Resist Updat 2012;15(3):133-48
46. Vakulenko BS, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003;16(3):430-50
47. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:479-87
48. Pfaller AM, Jones NR, Doern VJ, Kugler K; The Sentry Participants Group. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42(7):1762-70
49. Gonzalez LS III, Spencer JP. Aminoglycosides: a practical review. Am Fam Physician 1998;58(8):1811-20
50. Falagas ME, Karageorgopoulos DE, Georgantzi GG, et al. Susceptibility of Gram-negative bacteria to isepamicin: a systematic review. Expert Rev Anti Infect Ther 2012;10(2):207-18
51. Maraki S, Samonis G, Karageorgopoulos DE, et al. In vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece. Antimicrob Agents Chemother 2012;56(6):3067-73
52. Samonis G, Maraki S, Vouloumanou EK, et al. Antimicrobial susceptibility of non-fermenting Gramnegative isolates to isepamicin in a region with high antibiotic resistance. Eur J Clin Microbiol Infect Dis 2012;31(11):3191-8
53. Hwang JH, Lee JH, Moon MK, et al. The usefulness of arbekacin compared to vancomycin. Eur J Clin Microbiol Infect Dis 2012;31(7):1663-6
54. Daniels M, Hill AB. Chemotherapy of pulmonary tuberculosis in young adults. Br Med J 1952;1(4769):1162-8
55. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28
56. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000;283(17):2281-90
57. Infectious Diseases Society of America. Tularemia: current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis. Available from: http://biodefense.idsociety.org/idsa/bt/ tularemia/biofacts/tularemiafactsheet. html#-References-3) [Accessed 8 March 2013]
58. Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev 2012;10: CD007179-doi: 10.1002/14651858
59. Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for Treatment of Human Infections Caused by Bartonella Species. Antimicrob Agents Chemother 2004;48(6):1921-33
60. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. Engl J Med 1997;336(10):708
61. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39(9):1267-84
62. Murray B E. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3(1):46-65
63. Lorber B. Listeriosis. Clin Infect Dis 1997;24(1):1-9
64. Pintado V, Cabellos C, Moreno S, et al. Enterococcal meningitis: a clinical study of 39 cases and review of the literature. Medicine (Baltimore) 2003;82(5):346-64
65. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006;57(4):639-47
66. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009;48(6):713-21
67. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4(8):519-27
68. Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005;5(4):192-3
69. Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005;41(2):149-58
70. Bliziotis IA, Petrosillo N, Michalopoulos A, et al. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia. PLoS One 2011;6(10):e26470
71. Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000;160(4):501-9
72. van Delden C. Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int J Antimicrob Agents 2007;30(Suppl 1):S71-5
73. Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 2009;63(2):246-51
74. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006;(1):CD003344
75. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49(2):760-6
76. Micek ST, Welch EC, Khan J, et al. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia. J Hosp Med 2011;6(7):405-10
77. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010;54(5):1742-8
78. Zilberberg MD, Shorr AF, Micek ST, et al. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest 2008;134(5):963-8
79. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
80. Bailey JA, Virgo KS, DiPiro JT, et al. Aminoglycosides for intra-abdominal infection: equal to the challenge? Surg Infect (Larchmt) 2002;3(4):315-35
81. Falagas ME, Matthaiou DK, Karveli EA, Peppas G. Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. beta-lactam monotherapy for the treatment of intra-abdominal infections. Aliment Pharmacol Ther 2007;25(5):537-56
82. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50(2):133-64
83. Wood MJ, Farrell W. Comparison of urinary excretion of tobramycin and gentamicin in adults. J Infect Dis 1976;134(Suppl):S133-6
84. Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007;60(2):247-57
85. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011;55(12):5893-9
86. Gupta K, Hooton TM, Naber KG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52(5):e103-20
87. Badal R, Lob S, Bouchillon S, et al. Global trends in frequency and susceptibility of extended-spectrum blactamase positive E. coli, K. Pneumoniae, and K. oxytoca isolated from intra-abdominal infections since 2005-the SMART Study [Poster 1179]. Presented at: The 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 March-3 April 2012; London, UK
88. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006;12(4):315-21
89. Miller GH, Sabatelli FJ, Hare RS, et al. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 1997;24(Suppl 1):S46-62
90. Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem resistant Enterobacteriaceae isolates. JAC 2011;66:48-53
91. Zapor MJ, Barber M, Summers A, et al. In vitro activity of the aminoglycoside antibiotic arbekacin against acinetobacter baumannii- calcoaceticus isolated from war-wounded patients at walter reed army medical center. Antimicrob Agents Chemother 2010;54(7):3015-17
92. Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol 2012;12(5):527-34
93. Cass RT, Brooks CD, Havrilla NA, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother 2011;55(12):5874-80
94. Study for the treatment of complicated urinary tract infection and acute pyelonephritis. Available from: http:/clinicaltrials.gov/ct2/show/NCT01096849
95. Landman D, Kelly P, Backer M, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 2011;66(2):332-4
96. Endimiani A, Hujer KM, Hujer AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009;53(10):4504-7
97. Galani I, Souli M, Daikos GL, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 2012;24(4):191-4
98. Reyes N, Aggen JB, Kostrub CF. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob Agents Chemother 2011;55(4):1728-33
99. Lin G, Ednie LM, Appelbaum PC. Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob Agents Chemother 2010;54(5):2258-61
100. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010;13(6):151-71